JNJ
Johnson & Johnson Delivers Strong Q2 Results, Raises Full Year Guidance
Johnson & Johnson has delivered a strong second quarter performance, with operational sales growth of 4.6% across its business. The company reported $15 billion in quarterly sales from its Innovative Medicines segment, driven by double-digit growth across three brands: DARZALEX, CARVYKTI, and other products. This achievement is particularly impressive
